TP53 and breast cancer: In an example of sidestepping p53 when it is defective, it has been shown that while doxorubicin is capable of initiating cell death through inducing lysosomal leakage, the same treatment is unable to produce lysosomal leakage and cell death in breast cancer p53-mutant cell lines (Nguyen et al., 2022).